<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Scirica, Benjamin M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">TRA 2°P-TIMI 50 Results</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">23-24</style></pages><abstract><style  face="normal" font="default" size="100%">For patients with a history of myocardial infarction (MI) who are stable, the addition of vorapaxar to the standard of care reduced the long-term risk of cardiovascular death or ischemic events and increased the risk of moderate or severe bleeding. The efficacy and safety of the drug were evaluated for secondary prevention in a broad group of patients with prior MI, prior stroke, or peripheral artery disease in the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction 50 [TRA 2°P-TIMI 50] trial.</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>